Meningococcal B vaccine Bexsero will be funded from 1 March 2023 to protect against meningococcal disease in children up to 12 months of age, administered as part of the childhood immunisation programme. It will also be funded for people aged 13 to 25 years who are entering into or in their first year of specified close-living situations. Catch-up programmes will also be funded for these groups.

See our evidence review here.